#ASCO2017 – Biosimilar May Be As Effective as Trastuzumab for Early Breast Cancer
7 Jun, 2017 | 15:13h | UTC#ASCO2017 – CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary: Biosimilar May Be As Effective as Trastuzumab for Early Breast Cancer – Physician’s First Watch (free)